Literature DB >> 6179552

Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease.

A B Nichols, J Owen, K L Kaplan, R R Sciacca, P J Cannon, H L Nossel.   

Abstract

In vivo platelet alpha-granule release and fibrin I formation were measured in 82 patients with ischemic heart disease by radioimmunoassay of platelet factor 4, beta-thromboglobulin, and fibrinopeptide A. The presence and extent of coronary artery disease were determined by coronary arteriography, and the extent of left ventricular regional dysfunction was assessed by contrast left ventriculography. In patients with abnormal coronary arteriograms without previous myocardial infarction, mean levels of platelet factor 4, beta-thromboglobulin, and fibrinopeptide A were not elevated. In patients in whom myocardial infarction had occurred more than 6 mo previously, platelet factor 4 (8.3 ng/ml; p less than 0.01) and beta-thromboglobulin (33.2 ng/ml; p less than 0.001) levels were significantly elevated, but fibrinopeptide A levels were normal. Levels of platelet factor 4 and beta-thromboglobulin were unrelated to the extent of coronary artery disease. In the patients with prior infarction, beta-thromboglobulin correlated directly with extent of left ventricular regional dysfunction (r = 0.53; p less than 0.01) and inversely with ejection fraction (r = -056; p less than 0.05). In a small group of patients with left ventricular aneurysm, mean fibrinopeptide A levels were also elevated. We interpret these findings as indicating that platelet release in patients with ischemic heart disease results from platelet reaction with previously infarcted myocardium rather than with the atherosclerotic coronary arteries.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6179552

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Platelet activity and cardiovascular risk in apparently healthy individuals: a review of the data.

Authors:  Gaurav Sharma; Jeffrey S Berger
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

2.  Circulating levels of platelet α-granule cytokines in trauma patients.

Authors:  N A Windeløv; S R Ostrowski; P I Johansson; M Wanscher; C F Larsen; A M Sørensen; L S Rasmussen
Journal:  Inflamm Res       Date:  2015-02-20       Impact factor: 4.575

3.  Effects of beraprost sodium, a new prostaglandin I2 analog, on parameters of hemostasis, fibrinolysis, and myocardial ischemia in patients with exertional angina.

Authors:  K Sakata; T Hoshino; H Yoshida; T Kaburagi; A Takada
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

4.  Lack of association between haemostatic variables and the presence or the extent of coronary atherosclerosis.

Authors:  U Schmitz-Huebner; S G Thompson; L Balleisen; C Fechtrup; W Grosse-Heitmeyer; B Kirchhof; E Most; U S Müller; C Seiffert; D Seiffert
Journal:  Br Heart J       Date:  1988-03

5.  Thrombin and plasmin activity in coronary artery disease.

Authors:  M Small; G D Lowe; J T Douglas; I Hutton; A R Lorimer; C D Forbes
Journal:  Br Heart J       Date:  1988-09

6.  CXCL4 Plasma Levels Are Not Associated with the Extent of Coronary Artery Disease or with Coronary Plaque Morphology.

Authors:  Christian Erbel; Grigorios Korosoglou; Pearlyn Ler; Mohammadreza Akhavanpoor; Gabriele Domschke; Fabian Linden; Andreas O Doesch; Sebastian J Buss; Evangelos Giannitsis; Hugo A Katus; Christian A Gleissner
Journal:  PLoS One       Date:  2015-11-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.